(3aR,4S,7R,7aS)-2-((1R,2R)-2-(4-(1,2-Benzothiazol-3-yl)piperazin-1-ylmethyl)cyclohexylmethyl)hexahydro-4,7-methano-2H-isoindole-1,3-dione
| Title | Journal |
|---|---|
| Newer antipsychotics and upcoming molecules for schizophrenia. | European journal of clinical pharmacology 20130801 |
| Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography. | Psychopharmacology 20130101 |
| Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. | Expert review of clinical pharmacology 20130101 |
| Lurasidone in schizophrenia: new information about dosage and place in therapy. | Advances in therapy 20121001 |
| Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120901 |
| Iloperidone, asenapine and lurasidone: a primer on their current status. | Expert opinion on pharmacotherapy 20120901 |
| Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. | CNS drugs 20120901 |
| A review of published evidence reporting on the efficacy and pharmacology of lurasidone. | Expert opinion on pharmacotherapy 20120801 |
| Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? | Clinical schizophrenia & related psychoses 20120701 |
| 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. | Neuroreport 20120509 |
| The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. | Psychopharmacology 20120501 |
| Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. | International clinical psychopharmacology 20120501 |
| Lurasidone (latuda®): an atypical antipsychotic. | Issues in mental health nursing 20120501 |
| Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. | The international journal of neuropsychopharmacology 20120301 |
| New drugs 2012 part I. | Nursing 20120301 |
| Lurasidone for schizophrenia: what's different? | Expert review of neurotherapeutics 20120301 |
| The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. | Molecular pharmacology 20120201 |
| Update on the development of lurasidone as a treatment for patients with acute schizophrenia. | Drug design, development and therapy 20120101 |
| Lurasidone: an atypical antipsychotic for schizophrenia. | The Annals of pharmacotherapy 20120101 |
| Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. | Biomedical chromatography : BMC 20111201 |
| Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. | Xenobiotica; the fate of foreign compounds in biological systems 20111201 |
| Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. | Schizophrenia research 20111101 |
| Lurasidone: a new treatment option for schizophrenia. | Drugs of today (Barcelona, Spain : 1998) 20111101 |
| Biological perspectives: update on newer antipsychotic drugs: are they evidence based? | Perspectives in psychiatric care 20111001 |
| Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. | Psychopharmacology 20110901 |
| Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. | The American journal of psychiatry 20110901 |
| Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110801 |
| Pharmacokinetics and metabolism update for some recent antipsychotics. | Expert opinion on drug metabolism & toxicology 20110701 |
| The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. | Behavioural brain research 20110620 |
| Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. | Schizophrenia research 20110401 |
| Update on newer antipsychotic drugs. | Journal of psychosocial nursing and mental health services 20110401 |
| Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. | Postgraduate medicine 20110301 |
| Lurasidone (Latuda) for schizophrenia. | The Medical letter on drugs and therapeutics 20110221 |
| Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. | Schizophrenia research 20110201 |
| Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. | International journal of clinical practice 20110201 |
| Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. | Clinical schizophrenia & related psychoses 20110101 |
| New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride. | Journal of the American Pharmacists Association : JAPhA 20110101 |
| Lurasidone: a clinical overview. | The Journal of clinical psychiatry 20110101 |
| Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. | The Journal of pharmacology and experimental therapeutics 20100701 |
| Lurasidone: a new drug in development for schizophrenia. | Expert opinion on investigational drugs 20091101 |
| Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. | The Journal of clinical psychiatry 20090601 |
| Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. | Behavioural brain research 20080125 |
| Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. | European journal of pharmacology 20071031 |